13D Filing: RA Capital Management and Wave Life Sciences Ltd (WVE)

 

This
Amendment No. 1 amends and supplements the statement on Schedule 13D (the “Statement”) originally filed with the Securities
and Exchange Commission on November 27, 2015 by the Reporting Persons with respect to Ordinary Shares (the “Ordinary Shares”),
of Wave Life Sciences Ltd., a Singapore public limited company (the “Issuer”).   Unless
otherwise defined herein, capitalized terms used in this Amendment No. 1 shall have the meanings ascribed to them in the initial
Statement.

Item 3.

Source and Amount of Funds or Other Consideration

Item 3 of the Statement is hereby amended
and supplemented as follows:

On November 13, 2017, the Reporting Persons
purchased 400,000 Ordinary Shares for $9,320,000.00. On November 14, 2017, the Reporting Persons purchased 23,398 Ordinary Shares
for $561,549.66. All shares were purchased with working capital and were purchased in a separately managed account.

Item 4.

Purpose of Transaction

Item 4 is hereby supplemented as follows:

The Reporting Persons acquired the Ordinary
Shares referred to in Item 3 for investment purposes and not with an intent, purpose or effect of changing control of the Issuer.

Item 5.

Interest in Securities of the Issuer

(a) and (b) See Items 7-11 of the cover
pages and Item 2 above.

(c) The following table lists the Reporting
Persons’ transactions in Common Stock that were effected during the sixty day period prior to the filing of this Schedule
13D:

Transaction	Date	No. Shares	Price
Purchase	13-Nov-2017	400,000	$23.30
Purchase	14-Nov-2017	23,398	$23.9999

(d) Not applicable.

(e) Not applicable.

Item 7.

Material to Be Filed as Exhibits

Exhibit 1

Joint Filing Agreement by and among the Reporting Persons is incorporated herein by reference to Exhibit 1 to the Schedule 13D filed by the Reporting Persons with the Securities and Exchange Commission on November 27, 2015.